T

Transcenta Holding Limited
HKEX:6628

Watchlist Manager
Transcenta Holding Limited
HKEX:6628
Watchlist
Price: 2.16 HKD -3.14% Market Closed
Market Cap: 971.8m HKD

Transcenta Holding Limited
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Transcenta Holding Limited
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
T
Transcenta Holding Limited
HKEX:6628
Net Income (Common)
-ÂĄ290.3m
CAGR 3-Years
45%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Net Income (Common)
-ÂĄ5B
CAGR 3-Years
20%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Net Income (Common)
ÂĄ1.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Net Income (Common)
-ÂĄ514.5m
CAGR 3-Years
22%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Net Income (Common)
ÂĄ106.2m
CAGR 3-Years
-63%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Net Income (Common)
-ÂĄ266.8m
CAGR 3-Years
33%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Transcenta Holding Limited
Glance View

Market Cap
885.8m HKD
Industry
Biotechnology

Transcenta Holding Ltd. is a clinical stage global biopharmaceutical company that integrates the capacities of discovery, research, development, manufacturing and business development. The company is headquartered in Suzhou, Anhui. The company went IPO on 2021-09-29. The firm's products include MSB2311, TST001, TST005, TST002, TST004, TST003, TST008, MSB0254 and TST006. The firm's all products are in the research and development (R&D) stage and have not been commercialized. The firm also provides contract developmentand manufacturing organization (CDMO) services, mainly including process development services, GMP / cGMP production services, cell line development services, sample testing services, formula optimization services and drug formation research.

Intrinsic Value
0.72 HKD
Overvaluation 66%
Intrinsic Value
Price
T

See Also

What is Transcenta Holding Limited's Net Income (Common)?
Net Income (Common)
-290.3m CNY

Based on the financial report for Dec 31, 2024, Transcenta Holding Limited's Net Income (Common) amounts to -290.3m CNY.

What is Transcenta Holding Limited's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
6%

Over the last year, the Net Income (Common) growth was 37%. The average annual Net Income (Common) growth rates for Transcenta Holding Limited have been 45% over the past three years , 6% over the past five years .

Back to Top